JP2021505289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505289A5 JP2021505289A5 JP2020531574A JP2020531574A JP2021505289A5 JP 2021505289 A5 JP2021505289 A5 JP 2021505289A5 JP 2020531574 A JP2020531574 A JP 2020531574A JP 2020531574 A JP2020531574 A JP 2020531574A JP 2021505289 A5 JP2021505289 A5 JP 2021505289A5
- Authority
- JP
- Japan
- Prior art keywords
- microbubbles
- target tissue
- properties
- dosing
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 46
- 239000003814 drug Substances 0.000 claims description 29
- 229940124597 therapeutic agent Drugs 0.000 claims description 29
- 238000003860 storage Methods 0.000 claims description 28
- 238000005259 measurement Methods 0.000 claims description 18
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000009826 distribution Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000005728 strengthening Methods 0.000 claims description 8
- 239000002872 contrast media Substances 0.000 claims description 7
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 6
- 229960001101 ifosfamide Drugs 0.000 claims description 6
- 229960002247 lomustine Drugs 0.000 claims description 6
- -1 temozolomid Chemical compound 0.000 claims description 6
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 claims description 6
- 229960003048 vinblastine Drugs 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 3
- JHUJMHKRHQPBRG-UHFFFAOYSA-N 4-Hydroxyifosfamide Chemical compound OC1CCOP(=O)(NCCCl)N1CCCl JHUJMHKRHQPBRG-UHFFFAOYSA-N 0.000 claims description 3
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- 102100021906 Cyclin-O Human genes 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 3
- 150000008209 arabinosides Chemical class 0.000 claims description 3
- DRTQHJPVMGBUCF-CCXZUQQUSA-N arauridine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-CCXZUQQUSA-N 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 190000008236 carboplatin Chemical compound 0.000 claims description 3
- 229960005243 carmustine Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 238000000386 microscopy Methods 0.000 claims description 3
- 229960001420 nimustine Drugs 0.000 claims description 3
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 3
- KPMKNHGAPDCYLP-UHFFFAOYSA-N nimustine hydrochloride Chemical compound Cl.CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 KPMKNHGAPDCYLP-UHFFFAOYSA-N 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229960001196 thiotepa Drugs 0.000 claims description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 3
- 238000012795 verification Methods 0.000 claims description 3
- 230000007717 exclusion Effects 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000012538 light obscuration Methods 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762597073P | 2017-12-11 | 2017-12-11 | |
| US201762597071P | 2017-12-11 | 2017-12-11 | |
| US201762597076P | 2017-12-11 | 2017-12-11 | |
| US62/597,076 | 2017-12-11 | ||
| US62/597,073 | 2017-12-11 | ||
| US62/597,071 | 2017-12-11 | ||
| PCT/IB2018/001537 WO2019116095A1 (en) | 2017-12-11 | 2018-12-05 | Controlling delivery of therapeutic agent in microbubble-enhanced ultrasound procedures |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505289A JP2021505289A (ja) | 2021-02-18 |
| JP2021505289A5 true JP2021505289A5 (https=) | 2021-08-19 |
| JP7359765B2 JP7359765B2 (ja) | 2023-10-11 |
Family
ID=65276216
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531574A Active JP7359765B2 (ja) | 2017-12-11 | 2018-12-05 | 微小気泡強化超音波手技における治療剤の送達の制御 |
| JP2020531576A Active JP7502185B2 (ja) | 2017-12-11 | 2018-12-05 | 適応閉ループ超音波療法 |
| JP2020531629A Pending JP2021505295A (ja) | 2017-12-11 | 2018-12-11 | 微小気泡媒介超音波手技における外因性作用物質特性の制御 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531576A Active JP7502185B2 (ja) | 2017-12-11 | 2018-12-05 | 適応閉ループ超音波療法 |
| JP2020531629A Pending JP2021505295A (ja) | 2017-12-11 | 2018-12-11 | 微小気泡媒介超音波手技における外因性作用物質特性の制御 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US11806496B2 (https=) |
| EP (3) | EP3723855B1 (https=) |
| JP (3) | JP7359765B2 (https=) |
| CN (5) | CN116617589A (https=) |
| WO (3) | WO2019116107A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10219815B2 (en) | 2005-09-22 | 2019-03-05 | The Regents Of The University Of Michigan | Histotripsy for thrombolysis |
| US11179581B2 (en) | 2015-03-09 | 2021-11-23 | The Research Foundation For The State University Of New York | Systems and methods for promoting cellular activities for tissue maintenance, repair, and regeneration |
| WO2016210133A1 (en) | 2015-06-24 | 2016-12-29 | The Regents Of The Universtiy Of Michigan | Histotripsy therapy systems and methods for the treatment of brain tissue |
| US12179042B2 (en) | 2017-02-23 | 2024-12-31 | Oron Zachar | Transcranial ultrasound focusing |
| US11123575B2 (en) * | 2017-06-29 | 2021-09-21 | Insightec, Ltd. | 3D conformal radiation therapy with reduced tissue stress and improved positional tolerance |
| JP2022510654A (ja) | 2018-11-28 | 2022-01-27 | ヒストソニックス，インコーポレーテッド | 組織破砕システムおよび方法 |
| US20220161013A1 (en) * | 2019-04-04 | 2022-05-26 | Northwestern University | Improved delivery of drug therapy to the cns by ultrasound-based opening of the blood-brain barrier |
| US12151125B2 (en) * | 2019-06-06 | 2024-11-26 | Insightec Ltd. | Magnetic resonance (MR) performance in MR-guided ultrasound systems |
| US20210015511A1 (en) * | 2019-07-16 | 2021-01-21 | Applaud Medical Inc. | System and method for comminution of biomineralizations using microbubbles |
| US12409345B2 (en) | 2019-07-25 | 2025-09-09 | Insightec Ltd. | Aberration corrections for dynamically changing media during ultrasound therapy |
| US12246195B2 (en) | 2019-10-11 | 2025-03-11 | Insightec, Ltd. | Pre-treatment tissue sensitization for focused ultrasound procedures |
| US12303187B2 (en) * | 2019-11-29 | 2025-05-20 | Canon Medical Systems Corporation | Medical image processing apparatus |
| US20230000466A1 (en) | 2019-12-18 | 2023-01-05 | Insightec, Ltd. | Adaptive single-bubble-based autofocusing and power adjustment in ultrasound procedures |
| CA3169465A1 (en) | 2020-01-28 | 2021-08-05 | The Regents Of The University Of Michigan | Systems and methods for histotripsy immunosensitization |
| US12582386B2 (en) | 2020-03-05 | 2026-03-24 | Insightec Ltd. | Differential prediction of aberration corrections for ultrasound therapy |
| JP7834349B2 (ja) * | 2020-05-27 | 2026-03-24 | アチューン・ニューロサイエンシズ・インコーポレイテッド | 脳活動を変調するための超音波システムおよび関連デバイスおよび方法 |
| BR112022025722A2 (pt) | 2020-06-18 | 2023-03-07 | Histosonics Inc | Sistemas e métodos de acoplamento acústico e paciente de histotripsia |
| CN113198117B (zh) * | 2020-08-18 | 2023-12-22 | 于波 | 二氢卟吩衍生物与超声医疗系统的组合 |
| CA3190517A1 (en) | 2020-08-27 | 2022-03-03 | Timothy Lewis HALL | Ultrasound transducer with transmit-receive capability for histotripsy |
| CN113040814B (zh) * | 2021-03-11 | 2023-12-22 | 飞依诺科技股份有限公司 | 超声微泡空化设备的成像处理方法及成像处理系统 |
| IL308943A (en) | 2021-06-07 | 2024-01-01 | Univ Michigan Regents | All-inclusive ultrasound systems and methods that include histotripsy |
| WO2022260746A1 (en) | 2021-06-07 | 2022-12-15 | The Regents Of The University Of Michigan | Minimally invasive histotripsy systems and methods |
| US20250263798A1 (en) | 2021-07-01 | 2025-08-21 | Insightec Ltd. | Diagnostic and treatment monitoring based on blood-brain barrier disruption |
| EP4404847A4 (en) * | 2021-09-24 | 2025-10-29 | Washington University St Louis | SYSTEMS AND METHODS FOR ULTRASOUND-ACTIVATED LIQUID BIOPSY |
| CN118382482A (zh) | 2021-11-12 | 2024-07-23 | 医视特有限公司 | 用于短脉冲过程的超声自动聚焦 |
| US20250040912A1 (en) * | 2021-12-09 | 2025-02-06 | Insightec, Ltd. | Systems and methods for effective delivery of monoclonal antibodies to neurological targets |
| WO2024047580A1 (en) * | 2022-08-31 | 2024-03-07 | Insightec Ltd. | Enforced tissue residency of payload molecules by acoustic disruption |
| US12366583B2 (en) | 2022-10-24 | 2025-07-22 | West Virginia University Board of Governors on behalf of West Virginia University | Methods of improving neurodegenerative disorders by targeted delivery of therapeutic agents |
| EP4608504A1 (en) | 2022-10-28 | 2025-09-03 | Histosonics, Inc. | Histotripsy systems and methods |
| KR20260003742A (ko) | 2023-04-20 | 2026-01-07 | 히스토소닉스, 인크. | 치료 계획 및 요법을 위한 사용자 인터페이스들 및 작업 흐름들을 포함하는 히스토트립시 시스템들 및 연관된 방법들 |
| CN117064445B (zh) * | 2023-09-25 | 2026-03-27 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 一种低强度的聚焦超声换能器定位调控方法、装置及设备 |
| CN120305583B (zh) * | 2024-01-15 | 2026-01-06 | 北京大学 | 微气泡控制方法、装置、设备、介质及产品 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6740039B1 (en) * | 1999-08-20 | 2004-05-25 | Koninklijke Philips Electronics N.V. | Methods and apparatus for displaying information relating to delivery and activation of a therapeutic agent using ultrasound energy |
| US6716168B2 (en) | 2002-04-30 | 2004-04-06 | Siemens Medical Solutions Usa, Inc. | Ultrasound drug delivery enhancement and imaging systems and methods |
| JP2004275850A (ja) * | 2003-03-14 | 2004-10-07 | Hitachi Ltd | 超音波装置 |
| JP2009505768A (ja) | 2005-08-30 | 2009-02-12 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 複合撮像及び治療トランスデューサ |
| EP1933944A2 (en) * | 2005-08-30 | 2008-06-25 | Koninklijke Philips Electronics N.V. | Method of using a combination imaging and therapy transducer to dissolve blood clots |
| WO2007026300A1 (en) * | 2005-08-30 | 2007-03-08 | Koninklijke Philips Electronics, N.V. | Combination imaging and therapy transducer with therapy transducer amplifier |
| US8257338B2 (en) * | 2006-10-27 | 2012-09-04 | Artenga, Inc. | Medical microbubble generation |
| CN100551440C (zh) * | 2006-08-30 | 2009-10-21 | 中国人民解放军第三军医大学第二附属医院 | 一种用于肿瘤超声治疗的治疗型超声微泡及其制备方法 |
| US7974682B2 (en) * | 2006-11-22 | 2011-07-05 | Marcela Gonzalez Molezzi | System and method to adaptively control contrast-enhanced diagnostic imaging procedure |
| US8357112B2 (en) * | 2007-03-09 | 2013-01-22 | Koninklijke Philips Electronics N.V. | Method of controlling a release of a material carried by ultrasound sensitive particles |
| JP4279328B2 (ja) * | 2007-05-07 | 2009-06-17 | 株式会社日立製作所 | 超音波撮像システム |
| US20080311045A1 (en) * | 2007-06-06 | 2008-12-18 | Biovaluation & Analysis, Inc. | Polymersomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo |
| EP2240081A1 (en) * | 2007-12-21 | 2010-10-20 | Koninklijke Philips Electronics N.V. | Systems and methods for tracking and guiding high intensity focused ultrasound beams |
| CN101244028A (zh) * | 2008-02-05 | 2008-08-20 | 许川山 | 一种药物定位递送和定量控释系统 |
| US20090234231A1 (en) | 2008-03-13 | 2009-09-17 | Knight Jon M | Imaging Catheter With Integrated Contrast Agent Injector |
| US8425424B2 (en) * | 2008-11-19 | 2013-04-23 | Inightee Ltd. | Closed-loop clot lysis |
| WO2010062854A2 (en) * | 2008-11-26 | 2010-06-03 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Methods and compositions for using bleomycin-derivatized microbubbles |
| US8882672B2 (en) | 2008-12-29 | 2014-11-11 | Perseus-Biomed Inc. | Method and system for tissue imaging and analysis |
| EP2470287A4 (en) * | 2009-08-28 | 2015-01-21 | Univ Columbia | SYSTEMS, METHODS AND DEVICES FOR PRODUCING GAS-FILLED MICROBUBBLES |
| CN101642607B (zh) * | 2009-09-01 | 2012-11-28 | 西安交通大学 | 基于阵列换能器的低强度聚焦超声药物控释与监控装置 |
| EP2477550A4 (en) | 2009-09-15 | 2013-12-04 | Univ Columbia | SYSTEMS, METHODS AND DEVICES FOR MICROBUBBLES |
| US8932237B2 (en) | 2010-04-28 | 2015-01-13 | Insightec, Ltd. | Efficient ultrasound focusing |
| KR101875203B1 (ko) * | 2010-06-09 | 2018-07-06 | 리전츠 오브 더 유니버스티 오브 미네소타 | 초음파 치료의 전달을 제어하기 위한 이중 모드 초음파 트랜스듀서(ｄｍｕｔ) 시스템 및 방법 |
| JP2012213475A (ja) | 2011-03-31 | 2012-11-08 | Panasonic Corp | 超音波造影剤注入装置 |
| EP2744558B1 (en) | 2011-09-28 | 2019-10-30 | Koninklijke Philips N.V. | Automated ultrasound mediated delivery. |
| MX2014003957A (es) | 2011-10-05 | 2014-04-30 | Koninkl Philips Nv | Ensayos de suministro mediado de ultrasonido. |
| US10449395B2 (en) | 2011-12-12 | 2019-10-22 | Insightec, Ltd. | Rib identification for transcostal focused ultrasound surgery |
| WO2013166504A2 (en) * | 2012-05-04 | 2013-11-07 | University Of Houston | Targeted delivery of active agents using thermally stimulated large increase of perfusion by high intensity focused ultrasound |
| NL2008816C2 (en) | 2012-05-14 | 2013-11-18 | Univ Twente | Method for size-sorting microbubbles and apparatus for the same. |
| EP2869815A4 (en) * | 2012-07-08 | 2016-03-16 | Sunnybrook Health Sciences Ct | A SYSTEM AND METHOD FOR THE USE OF ULTRASOUND STIMULATED MICROBUBBLE EXPOSURES FOR THE INDUCTION OF CERAMIDA CUMULATION IN ENDOTHELIC AND TUMOR CELLS |
| CN103654842A (zh) * | 2012-09-19 | 2014-03-26 | 重庆融海超声医学工程研究中心有限公司 | 超声监控与靶向控释系统 |
| EP2906291B1 (en) * | 2012-10-12 | 2019-05-15 | Profound Medical Inc. | Multi-foci sonications for hyperthermia treatments using magnetic resonance-guided focussed ultrasound |
| EP2950737B1 (en) | 2013-01-29 | 2023-01-11 | Insightec Ltd. | Simulation-based focused-ultrasound treatment planning |
| KR20140103769A (ko) * | 2013-02-19 | 2014-08-27 | 삼성전자주식회사 | 초음파를 조사하는 방법 및 이를 이용한 초음파 장치 |
| JP6442788B2 (ja) | 2013-03-06 | 2018-12-26 | インサイテック・リミテッド | 超音波処置における周波数最適化 |
| CN103230648B (zh) * | 2013-04-24 | 2016-09-14 | 重庆医科大学 | 低强度聚焦超声分子显像与治疗系统 |
| CN103267800B (zh) * | 2013-05-03 | 2015-08-05 | 西安交通大学 | 空化微泡高信噪比超声快速成像及动态尺寸分布估计方法 |
| EP3046607A4 (en) * | 2013-11-26 | 2017-06-07 | Bayer Healthcare LLC | System and method for medical fluid identification and verification |
| US9949722B2 (en) * | 2013-12-03 | 2018-04-24 | University Of Virginia Patent Foundation | System and method for binding dynamics of targeted microbubbles |
| FR3025112A1 (fr) * | 2014-09-02 | 2016-03-04 | Univ Bordeaux | Methode de controle d'une zone ciblee du cœur, methode d'ablation d'une zone ciblee du cœur, systemes associes |
| CN105214742B (zh) * | 2015-10-10 | 2017-10-31 | 中国科学院深圳先进技术研究院 | 基于人工结构声场的微流体系统及操控微粒的方法 |
| WO2017066442A1 (en) * | 2015-10-15 | 2017-04-20 | Insightec, Ltd. | Systems and methods for avoiding mri-originated interference with concurrently used rf systems |
| GB201601053D0 (en) | 2016-01-20 | 2016-03-02 | Isis Innovation | Method and apparatus for generating bubbles |
| KR101859571B1 (ko) * | 2016-07-27 | 2018-05-21 | 주식회사 루트로닉 | 안과용 치료장치 및 이의 제어방법 |
| US20190151239A1 (en) * | 2016-07-28 | 2019-05-23 | Cerebral Therapeutics LLC | Infusing drug solution directly into brain fluid |
| US11103731B2 (en) | 2017-01-12 | 2021-08-31 | Insightec, Ltd. | Overcoming acoustic field and skull non-uniformities |
| US10575816B2 (en) * | 2017-01-25 | 2020-03-03 | Insightec, Ltd. | Cavitation localization |
-
2018
- 2018-12-05 WO PCT/IB2018/001603 patent/WO2019116107A1/en not_active Ceased
- 2018-12-05 WO PCT/IB2018/001537 patent/WO2019116095A1/en not_active Ceased
- 2018-12-05 CN CN202310668437.1A patent/CN116617589A/zh active Pending
- 2018-12-05 US US16/771,768 patent/US11806496B2/en active Active
- 2018-12-05 CN CN201880087835.1A patent/CN111655337B/zh active Active
- 2018-12-05 JP JP2020531574A patent/JP7359765B2/ja active Active
- 2018-12-05 JP JP2020531576A patent/JP7502185B2/ja active Active
- 2018-12-05 CN CN201880089076.2A patent/CN111712301B/zh active Active
- 2018-12-05 EP EP18842722.3A patent/EP3723855B1/en active Active
- 2018-12-05 EP EP18852736.0A patent/EP3723857A1/en not_active Withdrawn
- 2018-12-05 US US16/771,771 patent/US20210187331A1/en active Pending
- 2018-12-11 US US16/771,770 patent/US12076520B2/en active Active
- 2018-12-11 CN CN202211472933.1A patent/CN115779287A/zh active Pending
- 2018-12-11 CN CN201880088970.8A patent/CN111699022B/zh active Active
- 2018-12-11 EP EP18845443.3A patent/EP3723856B1/en active Active
- 2018-12-11 JP JP2020531629A patent/JP2021505295A/ja active Pending
- 2018-12-11 WO PCT/IB2018/001548 patent/WO2019116097A1/en not_active Ceased
-
2024
- 2024-09-02 US US18/822,462 patent/US20240416099A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505289A5 (https=) | ||
| JP7359765B2 (ja) | 微小気泡強化超音波手技における治療剤の送達の制御 | |
| JP2021505295A5 (https=) | ||
| JP7111744B2 (ja) | 血液脳関門の選択的標的開放のためのシステムおよび方法 | |
| EP3645117B1 (en) | Ultrasound frequency and microbubble size optimization in microbubble-enhanced ultrasound treatment | |
| US11358007B2 (en) | Ultrasound frequency and microbubble size optimization in microbubble-enhanced ultrasound treatment | |
| JP2020525168A5 (https=) | ||
| Bing et al. | Blood-brain barrier (BBB) disruption using a diagnostic ultrasound scanner and Definity® in mice | |
| JP2020525169A5 (https=) | ||
| Ho et al. | Spatially uniform tumor treatment and drug penetration by regulating ultrasound with microbubbles | |
| JP2021505290A5 (https=) | ||
| US20160287856A1 (en) | Systems and methods for opening a tissue | |
| JP2020520718A5 (https=) | ||
| Kenwright et al. | Wall-less flow phantom for high-frequency ultrasound applications | |
| Yang et al. | Effect of ultrasound contrast agent dose on the duration of focused-ultrasound-induced blood-brain barrier disruption | |
| Raut et al. | Impact of hydrostatic pressure on phase-change contrast agent activation by pulsed ultrasound | |
| Bhagavatheeshwaran et al. | Subharmonic signal generation from contrast agents in simulated neovessels | |
| Chau et al. | Ultrasound-enhanced penetration through sclera depends on frequency of sonication and size of macromolecules | |
| CN109045446A (zh) | 一种控制药物释放的方法与系统 | |
| TWI454247B (zh) | 同步監控超音波導引藥物傳輸機制的系統及其方法 | |
| Nam et al. | Acoustic Droplet Vaporization, Cavitation, and Therapeutic Properties of Copolymer‐Stabilized Perfluorocarbon Nanoemulsions | |
| Santos | Towards overcoming limitations on MRI-guided focused ultrasound hyperthermia-mediated drug delivery using thermosensitive liposomes | |
| Gomyo et al. | 2P5-16 Viscoelasticity Phantom and its Quantitative Assessment Methods with Shear Wave | |
| Fura et al. | Analysis of Sonovue Microbubble Sonication Parameters in the Context of the Development of a Safe and Effective Method of Blood-Brain Barrier Opening | |
| Smith | Effects of Dual-Frequency Ultrasound Excitation on the Cavitation of Microbubble Contrast Agents for Use in Tumor Ablation Therapy |